Pay in 4 interest-free payments of $7.44 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
AOD-9604 targets fat cells through selective activation of beta-3 adrenergic receptors on adipocytes, triggering lipolysis (fat breakdown) while simultaneously inhibiting lipogenesis (new fat formation)
It occurs in a variety of forms most of which are active within the body
Maintaining nerve cells and the nervous system
Peptides are also being investigated as potential biomarkers for chronic diseases, which could revolutionize early diagnosis and treatment
GLOW Dosing Protocol The standard protocol for GLOW is 2.8 mg per injection: 2 mg GHK-Cu with 400 mcg each of BPC-157 and TB-4
Reduced Lipogenesis: Studies suggest it may help inhibit the production of new fat cells, thereby helping the body maintain a healthier body composition
